Poseida Therapeutics (PSTX)
2.02
+0.02 (1.00%)
Upcoming Events
Latest Headlines
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 18, 2024 8:00 AM - PR NewsWire
Form 8-K Poseida Therapeutics, For: Apr 17
April 17, 2024 9:18 AM - SEC Filing
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
April 17, 2024 9:00 AM - PR NewsWire
Form S-3 Poseida Therapeutics,
April 8, 2024 5:01 PM - SEC Filing
Form 8-K Poseida Therapeutics, For: Apr 08
April 8, 2024 4:31 PM - SEC Filing
Poseida Therapeutics (PSTX) Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
April 8, 2024 12:05 PM - StreetInsider
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
April 8, 2024 12:00 PM - PR NewsWire
Form 4 Poseida Therapeutics, For: Apr 01 Filed by: Rizvi Syed Ali-aamir
April 3, 2024 4:04 PM - SEC Filing
Form 3 Poseida Therapeutics, For: Apr 01 Filed by: Rizvi Syed Ali-aamir
April 3, 2024 4:03 PM - SEC Filing
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 1, 2024 4:05 PM - PR NewsWire
Poseida Therapeutics (PSTX) Appoints Syed Rizvi as Chief Medical Officer
March 25, 2024 4:05 PM - StreetInsider
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
March 25, 2024 4:05 PM - PR NewsWire
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 19, 2024 4:05 PM - PR NewsWire
Poseida Therapeutics (PSTX) Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
March 13, 2024 4:05 PM - StreetInsider
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
March 13, 2024 4:05 PM - PR NewsWire
Poseida Therapeutics, Inc. (PSTX) Tops Q4 EPS by 12c
March 7, 2024 4:41 PM - StreetInsider
Form 10-K Poseida Therapeutics, For: Dec 31
March 7, 2024 4:32 PM - SEC Filing
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
March 7, 2024 4:08 PM - PR NewsWire
Form 8-K Poseida Therapeutics, For: Mar 05
March 7, 2024 4:07 PM - SEC Filing
Form 4 Poseida Therapeutics, For: Mar 01 Filed by: Mylet Johanna
March 4, 2024 5:30 PM - SEC Filing
Form 4 Poseida Therapeutics, For: Mar 01 Filed by: Gergen Mark J
March 4, 2024 5:19 PM - SEC Filing
Form 4 Poseida Therapeutics, For: Mar 01 Filed by: LEONHARDT HARRY J
March 4, 2024 5:19 PM - SEC Filing
Form 4 Poseida Therapeutics, For: Mar 01 Filed by: Warner Brent
March 4, 2024 5:19 PM - SEC Filing
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 4, 2024 4:05 PM - PR NewsWire
Form SC 13G/A Poseida Therapeutics, Filed by: FMR LLC
February 9, 2024 9:30 AM - SEC Filing
Form S-8 Poseida Therapeutics,
February 8, 2024 4:11 PM - SEC Filing
Form 4 Poseida Therapeutics, For: Feb 01 Filed by: Gergen Mark J
February 2, 2024 8:52 PM - SEC Filing
Form SC 13G Poseida Therapeutics, Filed by: BlackRock Inc.
January 31, 2024 2:10 PM - SEC Filing
Full Article List
